Dietary-Induced obese (DIO) mice and rat model

At Sygnature Discovery, our experienced in vivo pharmacology team has developed and validated diet-induced obese (DIO) mouse and rat models to investigate obesity, insulin resistance, and the dysfunction of related tissues and organs including skeletal muscle and kidney. These well-established models enable a quick start to your study and a seamless transition from the DIO induction phase to testing novel therapeutics.

Key features of our DIO mouse model are:

  • Continuously available (minimal lead in time)
  • Weight stable (allowing assessment of weight loss rather than inhibition of weight gain)
  • Marked adiposity (30-40% fat)
  • Moderate insulin resistance
  • Ectopic lipid deposition and liver steatosis
  • Elevated plasma lipids

Below is an example of a typical 4-week study using the DIO mouse model, which demonstrates the efficacy of the clinically effective GLP-1 receptor agonist, semaglutide.

We have also developed and validated a DIO rat model using female Wistar rats allowed to develop obesity by ad libitum access to a simplified cafeteria diet, consisting of high-fat chow, ground chocolate and ground peanuts to mirror a typical calorie-dense Western diet. The DIO rat model has excellent predictive validity and is produced on demand, with a 16-week lead time.

Twice-weekly administration of semaglutide reduces body weight in the DIO mouse

Body weight progression in DIO mice over time, showing significant increase compared to lean controls in a diet-induced obesity model.

Data are adjusted means (n=10). SEMS are calculated from the residuals of the statistical model. Data analysed by ANCOVA with body weight on Day 1 as covariate. Comparisons to vehicle were by multiple t test (***p<0.001). Values in parentheses are % change from vehicle on day 34. Arrows indicate dosing days.

Twice-weekly administration of semaglutide reduces cumulative daily food intake in the DIO mouse

Cumulative food intake in DIO mice compared to lean controls, highlighting hyperphagia associated with diet-induced obesity.

Data are adjusted means (n=10). SEMs are calculated from the residuals of the statistical model. Data analysed by ANCOVA with average food intake from Day -6 to Day p as covariate. Comparisons to vehicle were by multiple t test for (***p<0.001).

 

Twice-weekly administration of semaglutide reduces total adiposity in the DIO mouse

Plasma biomarker levels in DIO mice showing altered insulin, glucose, triglycerides and cholesterol, indicating metabolic dysregulation.

Body composition was performed by DEXA on mice anaesthetized with isoflurane using the Lunar PIXImus Densitometer on Day 28. Statistical analysis was by robust regression with treatment as a factor and Day 1 body weight and scanning order as covariates. Data are shown as adjusted means (n=10) and standard errors of the mean (SEM) were calculated from the residuals of the statistical models. Comparisons of treatments to the vehicle were by the multiple t-test for Semaglutide. Significant differences against the vehicle are denoted by *p<0.05,**P<0.01, ***P<0.001.

 

Twice-weekly administration of semaglutide reduces liver lipid content in the DIO mouse

Liver and adipose tissue weights in DIO mice vs lean controls, demonstrating fat accumulation in diet-induced obesity.

Data are shown as adjusted means (n=10) and SEM. Analysis was by robust regression or general linear model with treatment and termination team as a factor and Day 1 body weight and termination order as covariates. Comparisons of to vehicle were by the multiple t-test for Semaglutide. *p<0.05 and ***p<0.001.

 

Twice-weekly administration of semaglutide improves glucose tolerance in the DIO mouse

Impaired glucose tolerance in DIO mice during OGTT, illustrating metabolic dysfunction in a preclinical obesity model.

Data are shown as adjusted means (n=10) and standard errors of the mean (SEM) are calculated from the residuals of the statistical models. Analysis was by robust regression of log-transformed data with treatment as a factor, and Day 1 body weight and termination order as covariates. Comparisons of the vehicle were by the multiple t-test for Semaglutide *p<0.05, **p<0.01 and ***p<0.001.

 

Twice-weekly administration of semaglutide improves the plasma cholesterol profile in the DIO mouse

Altered plasma leptin and adiponectin levels in DIO mice, reflecting hormonal imbalance in obesity-related metabolic disease.

Data are adjusted means (10) and standard errors of the mean (SEM) are calculated from the residuals of the statistical models. Analysis was by robust regression or general linear model of untransformed data with treatment as a factor and bleeding order and day 1 body weight as covariates. Comparisons to vehicle were by the multiple t-test for Semaglutide *p<0.05 ***p<0.001.

Studies in dietary-induced obese rats and mice are customised for each client and can include measurements of various parameters.

 

 

Get in touch for more information or browse our models of metabolic disorders.